Most Read Articles
6 days ago
Short-term treatment with methotrexate at >0.5 defined daily dose (8.75 mg/week) may help reduce the risk of ischaemic stroke in rheumatoid arthritis (RA) patients, while hydroxychloroquine and sulfasalazine have neutral effects, a retrospective study has found.
05 May 2015

Probiotics are continuously gaining in popularity, but advice on the right type and the correct way to take them is as important as ever, says pharmacist Seema Rambisheswar.

28 Dec 2017
Varenicline, while effective for smoking cessation, appears to significantly elevate the risk of cardiovascular hospitalization and emergency department visits, particularly for new users, a recent study shows.
29 Nov 2017
Younger children appear to be more likely to experience behavioural side effects of antiepileptic drugs (AEDs), with the likelihood increasing if children with epilepsy have baseline hyperactivity/impulsivity, a retrospective study has found.

Infliximab, adalimumab show efficacy in psoriasis and IBD

09 Feb 2018

Infliximab and adalimumab are both effective for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, while other biologics have shown efficacy for some, but not all, of these indications, according to the results of a systematic review.

To evaluate therapeutic options for patients with psoriasis and concurrent inflammatory bowel disease (IBD), a total of 2,282 articles were identified, of which 132 were selected. These clinical studies, published from 1 January 1947 to 14 February 2017, focused on biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease.

The investigators selected randomized, controlled, double-blinded studies if available and, if not, the next highest level of available evidence.

Both infliximab and adalimumab had shown efficacy in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. Ustekinumab was effective against psoriasis, psoriatic arthritis and Crohn’s disease, while certolizumab had demonstrated efficacy in psoriatic arthritis and Crohn’s disease.

On the other hand, etanercept, secukinumab, brodalumab and ixekizumab were effective in psoriasis and psoriatic arthritis, but these medications could induce or worsen IBD. In addition, guselkumab was effective in psoriasis only.

This systematic review was limited by the absence of clinical trials involving treatment specifically for concurrent psoriasis and IBD.

“There is a significant association between psoriasis and IBD. Many treatments for psoriasis and psoriatic arthritis are also used for IBD,” according to the investigators.

In another systematic review, researchers found that biologic therapy was effective and safe for the treatment of hyperkeratotic palmoplantar psoriasis (PP). [Dermatol Ther (Heidelb) 2017;7:425-446]

“Adalimumab, guselkumab, ixekizumab, secukinumab and ustekinumab all showed >80-percent efficacy for the treatment of hyperkeratotic PP, while infliximab and ustekinumab showed moderate efficacy for the treatment of pustular PP, and infliximab was the most efficacious treatment for palmoplantar pustulosis,” they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
6 days ago
Short-term treatment with methotrexate at >0.5 defined daily dose (8.75 mg/week) may help reduce the risk of ischaemic stroke in rheumatoid arthritis (RA) patients, while hydroxychloroquine and sulfasalazine have neutral effects, a retrospective study has found.
05 May 2015

Probiotics are continuously gaining in popularity, but advice on the right type and the correct way to take them is as important as ever, says pharmacist Seema Rambisheswar.

28 Dec 2017
Varenicline, while effective for smoking cessation, appears to significantly elevate the risk of cardiovascular hospitalization and emergency department visits, particularly for new users, a recent study shows.
29 Nov 2017
Younger children appear to be more likely to experience behavioural side effects of antiepileptic drugs (AEDs), with the likelihood increasing if children with epilepsy have baseline hyperactivity/impulsivity, a retrospective study has found.